Countries, not manufacturers, are responsible for WHO moratorium on boosters

Moderna (MRNA) has maxed out on its manufacturing capacity for 2021 and has shifted its focus to 2022 and 2023 advanced purchasing orders for its COVID-19 vaccine, officials said Thursday.

The company reported $2.8 billion in vaccine revenue for the second quarter and anticipates pricing of doses will fall and impact revenue as more low- and middle-income countries become the dominant purchasers, according to officials on an earnings call.

In addition, Moderna expects the global pandemic to…


Source link

About search

Check Also

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

[unable to retrieve full-text content]European Stocks Drop With US Tech Rally Faltering: Markets Wrap  Yahoo Finance …

Leave a Reply

Your email address will not be published. Required fields are marked *